Search
Vicagrel
go.drugbank.com/drugs/DB16349InvestigationalVicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingAvasopasem manganese
go.drugbank.com/drugs/DB16354InvestigationalAvasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.
Anti-SARS-CoV-2 IgY
go.drugbank.com/drugs/DB16356Investigational-2) Chicken Egg Antibody (IgY) (COVID-19)). … Anti-SARS-CoV-2 IgY are chicken egg antibodies to SARS-CoV-2 which have the potential to provide temporary protection against the virus when administered as intranasal drops.
Synonyms: Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)MW33
go.drugbank.com/drugs/DB16358ExperimentalMW33 is a recombinant fully human antibody to SARS-CoV-2. … [L27411] This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
Anti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368Investigational[L27796] INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum. … Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine
Synonyms: Anti-SARS-CoV-2 equine immunoglobulin fragments F(ab')2Actoxumab
go.drugbank.com/drugs/DB16376InvestigationalActoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigationalAxatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated
Categories: Colony Stimulating Factor-1 Receptor BlockerEfineptakin alfa
go.drugbank.com/drugs/DB16395InvestigationalEfineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. … Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability.
Synonyms: Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (Rhil-7-Hyfc), Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).Efmarodocokin alfa
go.drugbank.com/drugs/DB16398InvestigationalEfmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Synonyms: HUMAN INTERLEUKIN 22 (1-146), FUSED TO HUMAN IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 4 (CH1(97-98), H(S10>P(158)), CH2(N67>G(227)))-(147-377), DIMER (156-156':159-159')-BISDISULFIDE, PRODUCED IN CHO CELLS,, INTERLEUKIN 22 (HUMAN (MATURE)) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (SYNTHETIC HUMAN .GAMMA.4-CHAIN FC REGION (81-GLYCINE)), DIMERRegdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnRegdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.